Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate

EU orphan designation number: EU/3/10/794   
Active ingredient: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate
Indication: Treatment of primary myelofibrosis
Sponsor: Sanofi-Aventis groupe
54 rue La Boétie, F-75008 Paris, France

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
11/10/2010 Centralised Orphan - Designation EMA/OD/069/10 (2010)6939 of 01/10/2010
08/02/2011 Centralised Orphan - Transfer of orphan designation EMEA/OD/069/10/T/01 (2011)781 of 04/02/2011
06/11/2012 Other procedure EMA/OD/069/10